The global Veterinary Oncology Market is projected to grow at a rapid pace during the forecast period, with a revenue CAGR of 10.6%. In 2022, the market size was USD 379.91 Million, and it is expected to reach USD 940.76 Million by 2032. Several factors are driving the growth of this market.
The increasing prevalence of cancer in companion animals, including dogs, cats, and horses, is a major factor contributing to the market's revenue growth. In the U.S. alone, nearly 6 million dogs and cats are diagnosed with cancer each year. The rising demand for veterinary oncology services is a direct result of the rapid increase in the prevalence of cancer in pets.
Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/6426
Additionally, the growing adoption rates of pets and the humanization of pets are also driving market growth. Pet owners, with their increasing disposable income, are willing to spend more on their pets' health, including cancer treatment. The availability of pet insurance that covers veterinary oncology services is also expected to contribute to market growth.
Key players in the Veterinary Oncology Market:
- Zoetis Inc.
- Elanco
- Boehringer Ingelheim International GmbH
- Dechra Pharmaceuticals PLC
- VetDC Inc.
- Aratana Therapeutics Inc.
- Rhizen Pharmaceuticals S.A.
- Regeneus Ltd.
- CanFel Therapeutics Inc.
Advancements in veterinary oncology, such as targeted therapies and immunotherapy, are significant drivers of market revenue growth. Targeted therapies specifically attack molecules or cells involved in cancer growth, while immunotherapy enhances the body's immune system to fight cancer. These treatments offer less invasive options with fewer side effects compared to traditional treatments like chemotherapy and radiation therapy.
However, the high cost of veterinary oncology services and the scarcity of skilled veterinary oncologists in developing countries are factors that could restrain market revenue growth.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/6426
The global veterinary oncology market is segmented based on animal type and cancer type. In terms of animal type, companion animals accounted for the largest revenue share in 2022. The increasing prevalence of cancer in companion animals and the rising adoption of pets globally contribute to the growth of this segment. The livestock segment is expected to grow steadily due to the rising demand for meat and dairy products, along with the prevalence of cancer in livestock.
Based on cancer type, lymphoma accounted for the largest revenue share in 2022. Factors such as exposure to environmental toxins, genetic predisposition, and infections contribute to the increasing prevalence of lymphoma in animals. Mast cell tumors are also expected to experience significant growth due to their high prevalence in companion animals and the availability of advanced diagnostic tools and treatment options.
In terms of regional analysis, North America held the largest revenue share in the global veterinary oncology market. The presence of key market players, technological advancements, and high pet ownership rates contribute to the region's market dominance. Europe is expected to have the fastest revenue growth rate, driven by increasing pet ownership and the rising prevalence of cancer in animals. The Asia Pacific region is also expected to contribute a considerable revenue share due to increasing awareness of animal health and welfare, rising pet adoption rates, and increasing disposable income.
To summarize, the global veterinary oncology market is experiencing significant growth due to the rising prevalence of cancer in companion animals, increasing pet adoption rates, and awareness about animal health. Technological advancements in veterinary oncology, such as targeted therapies and immunotherapy, are also driving market growth. However, challenges such as the high cost of services and a shortage of skilled veterinary oncologists in developing countries need to be addressed.
Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/6426
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports:
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact:
John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek